144053-98-5

Usage

Uses

Used in Pharmaceutical Industry:
Morpholin-2-ylMethanol hydrochloride is used as an intermediate compound for the synthesis of various pharmaceuticals, given its compatibility with a range of chemical reactions and its presence in the structure of several drugs. Its solubility in water facilitates its incorporation into formulations and its morpholine ring provides a versatile scaffold for further chemical modifications.
Used in Organic Chemistry:
In the field of organic chemistry, Morpholin-2-ylMethanol hydrochloride is used as a reagent or building block for the preparation of complex organic molecules. Its morpholine ring can be a key structural element in the synthesis of bioactive molecules, and its hydrochloride form can participate in various reactions, such as nucleophilic substitutions or condensation reactions.
Used in Laboratory Research:
Morpholin-2-ylMethanol hydrochloride is employed as a research tool in academic and industrial laboratories, where its water solubility and chemical properties are exploited for the investigation of biological processes or the development of new chemical methodologies. Its morpholine ring may be a point of interest for studying interactions with biological targets or for testing new synthetic routes.
Used in Industrial Applications:
In industrial settings, Morpholin-2-ylMethanol hydrochloride is used as a component in the production of specialty chemicals, where its morpholine ring and hydrochloride salt form contribute to the desired properties of the final products. Its solubility and reactivity make it a valuable asset in the synthesis of compounds used in various industries, such as coatings, adhesives, or materials science.

Upstream product

• 103003-01-6 morpholin-2-ylmethanol 
• 135065-69-9 tert-butyl 2-(hydroxymethyl)morpholine-4-carboxylate 
• 189321-66-2 4-(tert-butoxycarbonyl)morpholine-2-carboxylic acid 
• 40987-24-4 R,S-2-hydroxymethyl-4-benzylmorpholine 
• 135065-71-3 (R)-2-hydroxymethylmorpholine-4-carboxylic acid tert-butyl ester 
• 135065-76-8 tert-butyl (2S)-2-(hydroxymethyl)morpholine-4-carboxylate 
• 1313484-80-8 (2S)-4-(p-tolylsulfinyl)-2-[(trityloxy)methyl]morpholine 

Downstream Products

• 135065-69-9 tert-butyl 2-(hydroxymethyl)morpholine-4-carboxylate 
• 500702-97-6 benzyl (2S)-2-(hydroxymethyl)morpholine-4-carboxylate 

Relevant academic research and scientific papers

IRAK DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

NOVEL PYRIMIDINE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS

The present invention relates to novel chemical compounds derived from pyrimidines, to the method for preparing same, to the novel intermediates obtained, to the use thereof as drugs, to the pharmaceutical compositions containing same, and to the therapeutic use thereof as AKT inhibitors.

Sulfinamides as highly effective amine protecting groups and their use in the conversion of Amino alcohols into morpholines

1,2-Amino alcohols have been converted into morpholines by using sulfinamides as temporary protecting/activating groups on the amine. We have developed a procedure for the selective synthesis of monoprotected N-sulfinyl amino alcohols through a double sul

THIADIAZOLES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS

Disclosed are novel compounds of Formula (IA) and the pharmaceutically acceptable salts and solvates thereof. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and ischemia reperfusion injury, pain (e.g., acute pain, acute and chronic inflammatory pain, and neuropathic pain) using a compound of Formula (IA).

ISOTHIAZOLE DIOXIDES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS

Disclosed are novel compounds of the formula (IA): and the pharmaceutically acceptable salts and solvates thereof. D and E are different groups wherein one is N and the other is CR50. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and cardiac reperfusion injury, pain (e.g., acute pain, acute and chronic inflammatory pain, and neuropathic pain) using a compound of formula IA.

3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands

There are disclosed compounds of the formula or a pharmaceutically acceptable salt or solvate thereof which are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.

THIADIAZOLEDIOXIDES AND THIADIAZOLEOXIDES AS CXC- AND CC-CHEMOKINE RECEPTOR LIGANDS

Disclosed are novel compounds of the formula (IA) and the pharmaceutically acceptable salts and solvates thereof. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and cardiac reperfusion injury, acute pain, acute and chronic inflammatory pain, and neuropathic pain using a compound of formula (IA).